CARDLYTICS INC (CDLX)

US14161W1053 - Common Stock

3.8  +0.13 (+3.54%)

After market: 3.8 0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CDLX. CDLX was compared to 92 industry peers in the Media industry. CDLX has a bad profitability rating. Also its financial health evaluation is rather negative. CDLX has a expensive valuation and it also scores bad on growth.



1

1. Profitability

1.1 Basic Checks

In the past year CDLX has reported negative net income.
CDLX had a negative operating cash flow in the past year.
CDLX had negative earnings in each of the past 5 years.
CDLX had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

CDLX's Return On Assets of -68.74% is on the low side compared to the rest of the industry. CDLX is outperformed by 91.21% of its industry peers.
The Return On Equity of CDLX (-393.92%) is worse than 86.81% of its industry peers.
Industry RankSector Rank
ROA -68.74%
ROE -393.92%
ROIC N/A
ROA(3y)-33.65%
ROA(5y)-24.34%
ROE(3y)-112.81%
ROE(5y)-77.12%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of CDLX (53.54%) is better than 67.03% of its industry peers.
CDLX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CDLX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.57%
GM growth 5Y2.94%

1

2. Health

2.1 Basic Checks

CDLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CDLX has been increased compared to 1 year ago.
The number of shares outstanding for CDLX has been increased compared to 5 years ago.
Compared to 1 year ago, CDLX has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -4.01, we must say that CDLX is in the distress zone and has some risk of bankruptcy.
CDLX has a Altman-Z score of -4.01. This is amonst the worse of the industry: CDLX underperforms 85.71% of its industry peers.
A Debt/Equity ratio of 3.06 is on the high side and indicates that CDLX has dependencies on debt financing.
CDLX's Debt to Equity ratio of 3.06 is on the low side compared to the rest of the industry. CDLX is outperformed by 83.52% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.06
Debt/FCF N/A
Altman-Z -4.01
ROIC/WACCN/A
WACC4.83%

2.3 Liquidity

CDLX has a Current Ratio of 1.18. This is a normal value and indicates that CDLX is financially healthy and should not expect problems in meeting its short term obligations.
CDLX's Current ratio of 1.18 is on the low side compared to the rest of the industry. CDLX is outperformed by 62.64% of its industry peers.
A Quick Ratio of 1.18 indicates that CDLX should not have too much problems paying its short term obligations.
The Quick ratio of CDLX (1.18) is worse than 60.44% of its industry peers.
Industry RankSector Rank
Current Ratio 1.18
Quick Ratio 1.18

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.53% over the past year.
Looking at the last year, CDLX shows a decrease in Revenue. The Revenue has decreased by -3.00% in the last year.
The Revenue has been growing by 15.46% on average over the past years. This is quite good.
EPS 1Y (TTM)67.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1600%
Revenue 1Y (TTM)-3%
Revenue growth 3Y18.27%
Revenue growth 5Y15.46%
Sales Q2Q%-15.12%

3.2 Future

The Earnings Per Share is expected to decrease by -0.70% on average over the next years.
The Revenue is expected to decrease by -4.37% on average over the next years.
EPS Next Y-94%
EPS Next 2Y-0.7%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-14.13%
Revenue Next 2Y-4.37%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

0

4. Valuation

4.1 Price/Earnings Ratio

CDLX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CDLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.7%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

CDLX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CARDLYTICS INC

NASDAQ:CDLX (11/21/2024, 8:18:50 PM)

After market: 3.8 0 (0%)

3.8

+0.13 (+3.54%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap193.12M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -68.74%
ROE -393.92%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 53.54%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 3.06
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.18
Quick Ratio 1.18
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)67.53%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-94%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-3%
Revenue growth 3Y18.27%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y